Geode Capital Management
VERV

Geode Capital Management’s Verve Therapeutics VERV Stock Holding History

Geode Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,704,394
Closed -$19.1M – 4568
2025
Q2 		$19.1M Buy
1,704,394
+22,003
+1% +$125K ﹤0.01% 1982
2025
Q1 		$7.69M Buy
1,682,391
+56,611
+3% +$379K ﹤0.01% 2446
2024
Q4 		$9.17M Buy
1,625,780
+25,093
+2% +$142K ﹤0.01% 2432
2024
Q3 		$7.75M Buy
1,600,687
+40,915
+3% +$238K ﹤0.01% 2516
2024
Q2 		$7.61M Buy
1,559,772
+110,346
+8% +$694K ﹤0.01% 2490
2024
Q1 		$19.3M Buy
1,449,426
+319,263
+28% +$4.23M ﹤0.01% 1954
2023
Q4 		$15.8M Buy
1,130,163
+77,283
+7% +$958K ﹤0.01% 2056
2023
Q3 		$14M Buy
1,052,880
+96,153
+10% +$1.55M ﹤0.01% 2054
2023
Q2 		$17.9M Buy
956,727
+70,956
+8% +$1.18M ﹤0.01% 1921
2023
Q1 		$12.8M Buy
885,771
+38,038
+4% +$745K ﹤0.01% 2101
2022
Q4 		$16.4M Buy
847,733
+65,021
+8% +$1.72M ﹤0.01% 1908
2022
Q3 		$26.9M Buy
782,712
+315,492
+68% +$10.1M ﹤0.01% 1531
2022
Q2 		$7.14M Buy
467,220
+40,952
+10% +$634K ﹤0.01% 2480
2022
Q1 		$9.73M Buy
426,268
+135,800
+47% +$3.88M ﹤0.01% 2359
2021
Q4 		$10.7M Buy
290,468
+15,664
+6% +$658K ﹤0.01% 2399
2021
Q3 		$12.9M Buy
274,804
+242,702
+756% +$14.3M ﹤0.01% 2277
2021
Q2 		$1.93M Buy
+32,102
New +$1.33M ﹤0.01% 3276

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management's VERV Position: Q3 2025 in Review

Geode Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,704,394 shares — an estimated $19.1M sold.

Geode Capital Management first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $26.9M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Geode Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Geode Capital Management sold 1,704,394 Verve Therapeutics shares in Q3 2025, an estimated $19.1M.
  • Geode Capital Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Geode Capital Management's Verve Therapeutics position peaked at $26.9M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Geode Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.